Literature DB >> 11292721

Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide.

S T Test1, J Mitsuyoshi, C C Connolly, A H Lucas.   

Abstract

Previous studies have demonstrated an adjuvant effect for the C3d fragment of complement C3 when coupled to T-dependent protein antigens. In this study, we examined the antibody response to covalent conjugates of C3d and a T-independent antigen, the capsular polysaccharide of serotype 14 Streptococcus pneumoniae (PPS14). We prepared a conjugate of mouse C3d and PPS14 and compared its immunogenicity with that of a conjugate of PPS14 and ovalbumin (OVA). When BALB/c mice were immunized with PPS14-C3d, there was a significant increase in serum anti-PPS14 concentrations compared with either native PPS14 or control PPS14-glycine conjugates. This was accompanied by a switch in anti-PPS14 from predominantly immunoglobulin M (IgM) to IgG1 by day 25 following primary immunization. Following secondary immunization with PPS14-C3d, there was a marked booster response and a further increase in the ratio of IgG1 to IgM anti-PPS14. Although the primary antibody response to the PPS14-OVA conjugate exceeded that induced by immunization with PPS14-C3d, serum anti-PPS14 concentrations after a second injection of PPS14-C3d were nearly identical to those induced by secondary immunization with PPS14-OVA. Experiments with athymic nude mice suggested that T cells were not required for the adjuvant effect of C3d on the primary immune response to PPS14 but were necessary for enhancement of the memory response after a second injection of PPS14-C3d. These studies show that the adjuvant effects of C3d extend to T-independent antigens as well as T-dependent antigens. As a means of harnessing the adjuvant potential of the innate immune system, C3d conjugates may prove useful as a component of vaccines against encapsulated bacteria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292721      PMCID: PMC98257          DOI: 10.1128/IAI.69.5.3031-3040.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

Review 1.  Innate immunity--beginning to fulfill its promise?

Authors:  D T Fearon
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

2.  C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.

Authors:  T M Ross; Y Xu; R A Bright; H L Robinson
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

3.  Secondary IgG responses to type III pneumococcal polysaccharide. I. Kinetics and antigen requirements.

Authors:  H Braley-Mullen
Journal:  J Immunol       Date:  1975-11       Impact factor: 5.422

4.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Authors:  W P Hausdorff; J Bryant; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

5.  The role of the capsular polysaccharide in the activation of the alternative pathway by the pneumococcus.

Authors:  J A Winkelstein; J A Bocchini; G Schiffman
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

6.  The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2).

Authors:  P K Mongini; M A Vilensky; P F Highet; J K Inman
Journal:  J Immunol       Date:  1997-10-15       Impact factor: 5.422

7.  Prolonged C3 depletion by cobra venom factor in thymus-deprived mice and its implication for the role of C3 as an essential second signal for B-cell triggering.

Authors:  J Pryjma; J H Humphrey
Journal:  Immunology       Date:  1975-03       Impact factor: 7.397

Review 8.  B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms.

Authors:  Q Vos; A Lees; Z Q Wu; C M Snapper; J J Mond
Journal:  Immunol Rev       Date:  2000-08       Impact factor: 12.988

Review 9.  Pneumococcal vaccine.

Authors:  L G Rubin
Journal:  Pediatr Clin North Am       Date:  2000-04       Impact factor: 3.278

10.  Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses.

Authors:  M B Pepys
Journal:  J Exp Med       Date:  1974-07-01       Impact factor: 14.307

View more
  26 in total

Review 1.  Evolution of complement as an effector system in innate and adaptive immunity.

Authors:  J Oriol Sunyer; Hani Boshra; Gema Lorenzo; David Parra; Bruce Freedman; Nina Bosch
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  Contribution of C3d-P28 repeats to enhancement of immune responses against HBV-preS2/S induced by gene immunization.

Authors:  Li-Xin Wang; Wei Xu; Qing-Dong Guan; Yi-Wei Chu; Ying Wang; Si-Dong Xiong
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

Review 3.  Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.

Authors:  Franklin R Toapanta; Ted M Ross
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 4.  The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens.

Authors:  A Zandvoort; W Timens
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

5.  Depletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell-dependent protein carrier.

Authors:  Samuel T Test; Joyce K Mitsuyoshi; Yong Hu
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

6.  Recurrent infections in partial complement factor I deficiency: evaluation of three generations of a Brazilian family.

Authors:  A S Grumach; M F Leitão; V G Arruk; M Kirschfink; A Condino-Neto
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

7.  A self-assembling peptide acting as an immune adjuvant.

Authors:  Jai S Rudra; Ye F Tian; Jangwook P Jung; Joel H Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

8.  Immunoglobulins and complement factor C4 in adult rhinosinusitis.

Authors:  M Seppänen; J Suvilehto; M-L Lokki; I-L Notkola; A Järvinen; H Jarva; I Seppälä; O Tahkokallio; H Malmberg; S Meri; V Valtonen
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

Review 9.  Complement: an overview for the clinician.

Authors:  Juan Carlos Varela; Stephen Tomlinson
Journal:  Hematol Oncol Clin North Am       Date:  2015-04-04       Impact factor: 3.722

10.  Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Authors:  Joseph F Bower; Xinzhen Yang; Joseph Sodroski; Ted M Ross
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.